Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial

Table 1 Demographic characteristics and concomitant medications at baseline

Characteristics and medications		G-PUR®, n = 14	Placebo, n = 16	Total, n = 30
Age, yr		34 (range: 24–61)	35 (range: 20–73)	34 (range: 20–73)
Sex	Male	5 (35%)	4 (25%)	9 (30%)
	Female	9 (64%)	12 (75%)	21 (70%)
Duration of IBS symptoms, yr		12 (IQR: 6–19)	9 (IQR: 6–21)	11 (IQR: 6–20)
Duration of IBS diagnosis, yr		8 (IQR: 3–11)	2 (IQR: 1–11)	4 (IQR: 1–11)
BMI, kg/m2		21 (IQR: 20–25)	24 (IQR: 21–26)	23 (IQR: 20–26)
Smoking status	Non-smoker	9 (64%)	11 (69%)	20 (67%)
	Ex-smoker	3 (21%)	4 (25%)	7 (23%)
	Smoker	2 (14%)	1 (6%)	3 (10%)
Concomitant medications
Any concomitant medication		12 (86%)	15 (94%)	27 (90%)
Analgesics		2 (14%)	8 (50%)	10 (33%)
Drugs for functional gastrointestinal disorders		4 (29%)	5 (31%)	9 (30%)
Selective serotonin reuptake inhibitors		4 (29%)	4 (25%)	8 (27%)
Systemic antihistamines		5 (36%)	1 (6%)	6 (20%)
Loperamide PRN		2 (14%)	2 (13%)	4 (13%)
Antacids		1 (7%)	1 (6%)	2 (7%)
Hypnotics, sedatives, antipsychotics		0 (0%)	2 (13%)	2 (7%)
Tonics		1 (7%)	1 (6%)	2 (7%)
Systemic antibiotics1		0 (0%)	1 (6%)	1 (3%)
Digestives, incl. enzymes		1 (7%)	0 (0%)	1 (3%)
Drugs for constipation		1 (7%)	0 (0%)	1 (3%)

¹Macrolides, lincosamides and streptogramins.

BMI: Body mass index; IBS: Irritable bowel syndrome; IQR: Interquartile range; PRN: Pro re nata (as necessary).